Corporate strategy stories

Sep 21, 2026

Novo Nordisk shares fall as investors react coolly to long-term growth strategy

Novo Nordisk's stock plummeted after the company's Capital Markets Day in London failed to reassure investors about its ability to compete in the crowded weight loss drug market, with CEO Lars Fruergaard Jørgensen presenting a roadmap targeting $23 billion in revenue by 2035. Investors expressed concerns about the drugmaker's post-Wegovy growth prospects despite plans to expand its pipeline through acquisitions.

Sep 21, 20265 sources

Sep 20, 2026

Novo Nordisk cuts 13,000 jobs as CEO outlines strategy beyond weight-loss drugs

Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.

Sep 20, 20269 sources

Jul 31, 2026

IBM CEO says quantum computing will contribute to revenue by 2028

IBM CEO Arvind Krishna stated the company expects quantum computing to measurably affect revenue and profit by 2028 or 2029, projecting $1 trillion in value from the technology by the end of the 2030s.

Jul 31, 20262 sources

Jun 16, 2026

Snap Launches $2,195 Consumer AR Glasses as CEO Defends Long-Term Strategy

Snap released its first consumer augmented-reality glasses priced at $2,195, positioning them as the future of AI-age interaction. CEO Evan Spiegel defended the product against activist investor pressure to shut down or spin off the hardware division.

Jun 16, 20262 sources

May 5, 2026

GameStop Makes $55.5 Billion Takeover Offer for eBay

Video game retailer GameStop offered to acquire eBay for $55.5 billion in an unsolicited bid that could turn hostile if rebuffed. The move would give GameStop control of a company four times its size.

May 5, 20262 sources

GameStop Proposes $55.5 Billion Unsolicited Bid to Acquire eBay

GameStop unveiled a non-binding $55.5 billion proposal to acquire eBay at $125 per share, a 46% premium, combining cash and stock in equal amounts.

May 5, 20264 sources

Top claims

▪Novo Nordisk's pipeline targets for expansion beyond diabetes and obesity include blood and endocrine disorders, liver diseases, and cardiovascular disease.
▪BMO Capital Markets noted that CagriSema's superiority over a low 5 mg dose of tirzepatide in type 2 diabetes is less impactful because tirzepatide previously beat CagriSema in obesity trials.
▪Novo Nordisk's active ingredient semaglutide, used in Wegovy and Ozempic, is scheduled to lose key patent exclusivity in the United States starting in 2032.

People involved

Arvind Krishna

Subtopics

E-commerce2 Mergers & acquisitions (M&A)2 Pharma2 Retail industry2 Weight loss drugs2 AI assistants & chatbots1 Consumer technology1 Drug pricing1 Mergers and acquisitions1 Novo Nordisk1 Pharmaceutical Industry1 Quantum computing1 SNAP1 Stock market performance1

Related timelines